P05.org

Sign in Subscribe

Latest — 12 Aug 2026

Created, Not Bought: The Shape of a Vaccine Royalty Trade

An earlier piece on this site, The Landscape of Vaccine Royalties and Royalty Financing, mapped how vaccine royalty streams arise, how they differ from therapeutic royalties, which deals have printed, and how the messenger RNA patent wars redistributed the economics of the pandemic products. It ended on an observation it

More issues

Nobody Holds It Long Enough: What Animal Health Royalties Need to Become an Asset Class

A royalty market can fail in three ways. There can be no cash flow, in which case there is nothing to discuss. There can be cash flow and no price, which is the biosimilar case: a stream exists, both sides can see it, and no number satisfies buyer and seller

The Royalty Nobody Buys: Why Biosimilars Generate Cash Flow and No Bid

A royalty market prices duration. A biosimilar is an asset engineered to have none. That single sentence explains most of what follows, but not the part that matters. The absence of a biosimilar royalty market is not a gap waiting to be filled. It is an equilibrium, held in place

The Weekly Term Sheet (2026-W32)

The largest story of the week did not happen. The FT reported, and Reuters corroborated, AstraZeneca and Bristol Myers Squibb merger talks near $400B; the market priced it (AZN as much as -9%, BMY +4-6%) and a senior source categorically denied it on Aug 5. Announced M&A

Reject, assume, assign: section 365 and the pharmaceutical royalty

Section 365 of the Bankruptcy Code is the estate's power to reject, assume, or assign the executory contracts a royalty depends on. This is a practitioner's account of how each power reaches a pharmaceutical stream, worked through the filings, at the deal level and the fund

Fund of the week: Janus Henderson (Healthcare)

Janus Henderson's Healthcare Team is the life-sciences franchise of Janus Henderson Group, a global active asset manager that ran approximately $480 billion at 31 March 2026. It runs the Global Life Sciences strategy (from 1998), a biotechnology franchise built out from 2018, and a biotech long/short

Company of the week: Taisho Pharmaceutical

Taisho is a century-old, cash-generative over-the-counter giant whose royalties run in both directions, outward on a prescription pipeline it mostly rents, inward on a consumer brand it licenses to the world-

When the Money Stops Early: How a Pharmaceutical Royalty Is Extinguished Before Term

A royalty's contractual term is the longest the stream can live, not the length it will live. Between the date the money starts and the date the contract says it stops, the stream is exposed to six mechanisms that can cut it off early, each with its own

Subscriber Special:What an AstraZeneca and Bristol Myers Squibb combination would mean for the royalty layer

The claims ahead of the royalty: encumbrances in pharmaceutical royalty finance

A royalty buyer acquires a place in a payment order that was fixed before it arrived. This is a guide to what ranks ahead of it, where each senior claim is documented, and what a diligence process has to test.

About

P05.org

Weekly structural analysis on pharmaceutical royalty financing. Deal mechanics, legal events, fund positioning, primary sources.

Topics